Go back

Davos delegates strike Ebola vaccine deal

Governments and philanthropists meeting at the World Economic Forum in Davos have pledged $5 million to stockpile an Ebola vaccine.

The deal, struck between the Gavi Alliance and the pharmaceutical company Merck, commits to generating 300,000 doses of the investigational vaccine by May. This will be an advanced-purchase commitment, under the condition that Merck will submit an emergency-use authorisation listing with the World HealO, to allow the vaccine to be used during future Ebola outbreaks.

Meanwhile, a full regulatory application will be submitted by 2017 for the vaccine. The drug, called the VSV Ebola vaccine or rVSV/ZEBOV-GP, has already undergone efficacy trials at sites in Africa, the United States, Canada and the European Union. Interim results from a trial in Guinea indicated the vaccine could be effective against Ebola.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.